Publications

Christine Voors-Pette, Kristell Lebozec, Peter Dogterom, Laurie Jullien, Philippe Billiald, Pauline Ferlan, Lionel Renaud, Olivier Favre-Bulle, Gilles Avenard, Matthias Machacek, Yannick Plétan, Martine Jandrot-Perrus. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arteriosclerosis, Thrombosis, and Vascular Biology. 39:956–964, 2019.

Machacek, M.,Lionel Renaud, Michel Enderlin-Paput, Christopher Kohl, Peter Seiler. Levofloxacin PK/PD in a mouse model of complicated urinary tract infection and its translation to clinical response using a mechanistic model of bacterial kill kinetics. ECCMID, P2127, 2019.

Machacek, M, L. Renaud, C. Kohl, M. Vercauteren, L. Remen, R. Welford. A Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. PAGE 27, Abstr 8470, 2018.

U. Keilholz, L. Rohde, P. Mehlitz, M. Knoedler, A. Schmittel, V. Kümmerlen, K. Klinghammer. P. Treasure, M. Lassus, G. Steventon, M. Machacek, N. Utku. First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. European Journal of Cancer. 80:14-25, 2017.

A. Krause, M. Machacek, D. Lott, N. Hurst, S. Bruderer, J. Dingemanse. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients with Pulmonary Arterial Hypertension. CPT: Pharmacometrics & Systems Pharmacology. 6 (7): 477-485, 2017

Machacek M, Renaud L, Wach A, Zwingelstein C, Beni L, Dale GE. 2017. Population pharmacokinetics modeling of murepavidin (POL7080) and simulation of target attainment in a population with ventilator-associated pneumonia due to infection with Pseudomonas aeruginosa, Abstr. 2729. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, Vienna, Austria.

Jimmy A Rotolo, Ricardo A. Ramirez, Raymond Schuch, Matthias Machacek, Tatiana Khariton, Parviz Ghahramani, and Michael Wittekind. PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose. ASM Microbe 2016, June 18.

Matthias Machacek, Lionel Renaud, Sasa Dimitrijevic, Debora Schmitz, Elena Ivanova, Karin Jorga. Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. J Clin Oncol 34, 2016 (suppl; abstr e14101).

Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen. Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. J Clin Oncol 34, 2016 (suppl; abstr e15602).